Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD

Executive VP & General Counsel Dieter David executed a pre-planned 10b5-1 open-market sale of 6,224 shares (6.40% of his prior direct stake) on March 9, 2026 for ~$228,110, leaving him with 91,047 shares (~$3.39M post-close value). Collegium is shifting toward ADHD therapeutics: Jornay PM grew 48% in its first full year and is guiding $190–$200M for 2026 (~31% growth), with total company revenue guided to $805–$825M; ten days after the sale the company announced a $650M acquisition of AZSTARYS. The insider sale appears routine and pre-scheduled, so it carries limited negative signal for investors relative to the company’s positive growth trajectory and strategic M&A move.

Analysis

The firm's shift toward CNS/ADHD assets materially changes the risk profile even if headline revenues look stable: regulatory and litigation tail risks tied to opioid exposure decline, while payor and formulary negotiation risk rises. ADHD brands live and die by prescription trends and preferred status on commercial formularies, so unit-volume sensitivity and gross-to-net dynamics will matter more than legacy price/mix drivers going forward.

A mid-sized, strategic acquisition for a company of this scale is a levered bet on commercialization and cross-selling: financing structure (cash vs. debt vs. equity) and the cadence of integration costs will determine near-term free cash flow and leverage metrics. If management leans on leverage, credit-sensitive indicators (interest coverage, covenant tests) will become high-probability catalysts and could force more conservative capital allocation or sell-side downgrades within 6–12 months.

Second-order beneficiaries include specialty pharmacies and CNS-focused sales platforms that can quickly absorb incremental ADHD script volume; suppliers of abuse-deterrent opioid components see less strategic emphasis. Competitive risk is concentrated — larger CNS incumbents can defend formulary placement and national accounts, so execution friction in payer negotiations or sample-to-prescription conversion could compress the implied upside materially.

The insider trim executed under a trading plan is a governance-neutral datapoint; market focus should be on operational cadence. Watch the next 2–4 quarterly prescription and gross-to-net readouts and any capital markets actions as the real inflection points — these will move sentiment faster than incremental insider transactions.

Key Decisions for Investors

• Initiate a tactical long in COLL (2–3% portfolio weight) on a >8–12% share-price pullback within the next 3 months; horizon 9–18 months. R/R: asymmetric upside if script ramp and formulary wins materialize, downside capped by execution risk—expect potential 30–60% upside vs 30–40% downside in adverse scenarios.
• Buy a 9–12 month call spread on COLL to capture upside while limiting premium outlay (buy nearer-term ATM/near-ATM call, sell a higher strike ~1.3x). This offers ~3:1+ gross upside if post-acquisition integration accelerates prescriptions, with max loss = net premium.
• Existing holders: implement a funded collar (buy 6–9 month puts ~20% OTM, sell 6–9 month calls ~10–20% OTM) to protect against integration or financing shocks while monetizing some time premium. This is cost-effective insurance ahead of upcoming quarterly prescription/gross-to-net prints.
• Event-driven short trigger: if management finances future tuck-ins with equity issuance or adds high incremental leverage with weak covenants, initiate a small short position in COLL (or buy puts) as a 3–6 month tactical trade — downside risk concentrated around dilution and credit repricing.